Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

givastomig (TJ-CD4B)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

ABL Bio, I-Mab

Drug class:

CLDN18.2 inhibitor, CD137 agonist

Related drugs:

‹

zolbetuximab (11)

TAC101-Claudin18.2 (0)

ALG.APV-527 (1)

PF-08046049 (1)

PF-05082566 (1)

›

CLDN18.2 expression	Gastroesophageal Cancer	CLDN18.2 expression	Gastroesophageal Cancer	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3
CLDN18.2 expression	Solid Tumor	CLDN18.2 expression	Solid Tumor	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	nivolumab + TJ-CD4B Sensitive: D – Preclinical nivolumab + TJ-CD4B Sensitive : D	nivolumab + TJ-CD4B Sensitive: D – Preclinical nivolumab + TJ-CD4B Sensitive : D